ArticleFood science & nutrition2025
Acrylamide Intake and Metabolic Syndrome Risk: The Tehran Lipid and Glucose Study.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protective Potential of Vinpocetine on Acrylamide Induced Liver Toxicity in Male Albino Rats.Journal of biochemical and molecular toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This cohort study aimed to determine the relationship between acrylamide intake and the risk of metabolic syndrome (MetS) and its risk factors in Tehranian adults. A total of 1762 men and 2786 women, respectively, with a mean ± SD age of 38.6 ± 14.3 and 35.9 ± 11.8 years and body mass index of 25.8 ± 4.31 were evaluated in this secondary analysis of the Tehran Lipid and Glucose Study. Dietary data were collected using a standard food frequency questionnaire. Total acrylamide intake was computed using the amount of acrylamide measured in 30 food items. MetS was defined according to the Iranian-modified National Cholesterol Education Program. Multivariable Cox proportional hazard regression models were used to estimate the incidence of MetS and its risk factors associated with acrylamide intake, considering confounding factors (e.g., age, sex, physical activity, body mass index, smoking). During the average follow-up of 6.23 ± 2.58 years, 1279 (28% of total) subjects had MetS incidence. The incidence of MetS was not associated with quartiles of acrylamide intake. After adjusting for confounding factors, participants in the fourth quartile of acrylamide intake had 15% and 21% higher risk of high triglyceride and high waist circumference, respectively. Moreover, acrylamide intake was positively related to high blood pressure incidence (Hazard ratio [Confidence interval] Q1-Q4: 1, 1.0 [0.92-1.08], 1.10 [1.02-1.19], 1.16 [1.07-1.26],
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.